ERT acquires invivodata

Monday, July 9, 2012 01:38 PM

ERT, a global technology-driven provider of health outcomes services, has decided to acquire invivodata, a provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, Penn.

The transaction was facilitated by the San Francisco-based private equity group, Genstar Capital, which last week completed its acquisition of ERT. The invivodata acquisition immediately positions ERT as a leader in clinical outcome assessments (COA). The combined organization will now offer sponsors, CROs and other third-party vendors a combination of market-leading electronic patient reported outcomes (ePRO)/COA solutions and scientific and regulatory consulting services that is unrivalled in the industry.

The invivodata consulting group bolsters ERT’s position in health outcomes research and complements its market leading position in cardiac safety and respiratory outcomes assessment. The acquisition also enhances ERT’s multi-mode ePRO product portfolio with the introduction of a suite of proven site-based and patient-friendly handheld devices that have already been validated to collect therapy-specific diaries, instruments and assessments.

“For some time, ERT has been working in collaboration with sponsors and partners to establish a new model of delivering value through the centralization of health outcomes data,” said Jeffrey Litwin, CEO of ERT. “By adding invivodata’s team of scientists and technology experts, we accelerated this strategic initiative, which will provide our joint clients with consistent, scientifically accurate outcome assessment data which will be accessible from one platform.”

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs